ScholarLens Back to search
2002•The Practical Journal of CancerRequires access

Chemotherepy of Vinorelbine Plus Cisplatin for Non-Small-Cell Lung Cancer

Hu Zhang

Open publisher page 0 citations

Abstract

Objective To compare the therapeutic effects and toxicity of Novelbine (NVB) plus Cisplatin (DDP) for the treatment of non small cell lung cancer (NSCLC).Methods 40 cases of NSCL were treated with NP (NVB 25 mg/m 2 iv gtt D1,8 plus DDP 30 mg/m 2 iv gtt D1,3).Results The total effective rate(CR+PR) were 40%.in denocarcinoma group,35%;in sguamous carcinoma group 42%.The difference between the two groups was not statistically significant ( P 0.05).In primary therepy group,it was 44%,in duplicate therepy group 33%.The difference between the two group was not statistically significant ( P 0.05) .Toxicity:White Blood Cell (Ⅲ°and Ⅳ°) decreased in 70%,Ⅳ°18%,Blood platelet (Ⅲ°andⅣ°)decreased in was 23%,Ⅳ°18%.No other serious side reactions occurred.Conclusion The NP regimen can obtain good resules.While the adverse effects are well tolerable.

About this research paper

What this paper is about

Objective To compare the therapeutic effects and toxicity of Novelbine (NVB) plus Cisplatin (DDP) for the treatment of non small cell lung cancer (NSCLC).Methods 40 cases of NSCL were treated with NP (NVB 25 mg/m 2 iv gtt D1,8 plus DDP 30 mg/m 2 iv gtt D1,3).Results The total effective rate(CR+PR) were 40%.in denocarcinoma group,35%;in sguamous carcinoma group 42%.The difference between the two groups was not statistically significant ( P 0.05).In primary therepy group,it was 44%,in duplicate therepy group 33%.The difference between the two group was not statistically significant ( P 0.05) .Toxicity:White Blood Cell (Ⅲ°and Ⅳ°) decreased in 70%,Ⅳ°18%,Blood platelet (Ⅲ°andⅣ°)decreased in was 23%,Ⅳ°18%.No other serious side reactions occurred.Conclusion The NP regimen can obtain good resules.While the adverse effects are well tolerable.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To compare the therapeutic effects and toxicity of Novelbine (NVB) plus Cisplatin (DDP) for the treatment of non small cell lung cancer (NSCLC).Methods 40 cases of NSCL were treated with NP (NVB 25 mg/m 2 iv gtt D1,8 plus DDP 30 mg/m 2 iv gtt D1,3).Results The total effective rate(CR+PR) were 40%.in denocarcinoma group,35%;in sguamous carcinoma group 42%.The difference between the two groups was not statistically significant ( P 0.05).In primary therepy group,it was 44%,in duplicate therepy group 33%.The difference between the two group was not statistically significant ( P 0.05) .Toxicity:White Blood Cell (Ⅲ°and Ⅳ°) decreased in 70%,Ⅳ°18%,Blood platelet (Ⅲ°andⅣ°)decreased in was 23%,Ⅳ°18%.No other serious side reactions occurred.Conclusion The NP regimen can obtain good resules.While the adverse effects are well tolerable.

Key concepts: Cisplatin, Vinorelbine, Lung cancer, Medicine, Toxicity, Internal medicine, Regimen, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Chemotherepy of Vinorelbine Plus Cisplatin for Non-Small-Cell Lung Cancer — Research Paper | ScholarLens